All In Biotech

Drug Trial Radar · NCT06673498

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery: a Prospective, Multicentre, Single-arm Clinical Study

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 10, 2024

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Anhui Provincial HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.

Conditions

  • Thrombocytopenia

Interventions

  • Lusutrombopag combined with recombinant human thrombopoietinDrug

    After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of respondents at day 8Time frame: Day 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • No.2 People's Hospital of Fuyang city

    Fuyang, Anhui, China · Recruiting

  • Anhui province hospital

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.